MX2021002311A - Metodo para producir un compuesto tetraciclico. - Google Patents

Metodo para producir un compuesto tetraciclico.

Info

Publication number
MX2021002311A
MX2021002311A MX2021002311A MX2021002311A MX2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A
Authority
MX
Mexico
Prior art keywords
producing
tetracyclic compound
producing tetracyclic
compound
carbonitrile
Prior art date
Application number
MX2021002311A
Other languages
English (en)
Inventor
Hiroki Serizawa
Akira Kawase
Hiroshi Fukuda
Naoto HAMA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021002311A publication Critical patent/MX2021002311A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta invención se refiere a un método para fabricar 9-etil-6,6-dimetil-8-[4-(morfolin-4-il)piperidin-1-il]-11-oxo-6,1 1-dihidro-5H-benzo[b]carbazol-3-carbonitrilo, y es industrialmente preferible, lo que permite obtener una sustancia objetiva en alto rendimiento de manera más segura y fácil que con el método convencional. Esquema 1 (ver Fórmulas).
MX2021002311A 2018-09-04 2019-09-03 Metodo para producir un compuesto tetraciclico. MX2021002311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
PCT/JP2019/034543 WO2020050241A1 (ja) 2018-09-04 2019-09-03 ４環性化合物の製造方法

Publications (1)

Publication Number Publication Date
MX2021002311A true MX2021002311A (es) 2021-04-28

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002311A MX2021002311A (es) 2018-09-04 2019-09-03 Metodo para producir un compuesto tetraciclico.

Country Status (14)

Country Link
US (1) US11939322B2 (es)
EP (1) EP3848361A4 (es)
JP (1) JP7167171B2 (es)
KR (1) KR102635225B1 (es)
CN (1) CN112585126B (es)
AR (1) AR116113A1 (es)
AU (1) AU2019337018B2 (es)
BR (1) BR112021001145A2 (es)
CA (1) CA3107270A1 (es)
IL (1) IL281079A (es)
MX (1) MX2021002311A (es)
SG (1) SG11202100983XA (es)
TW (1) TWI825163B (es)
WO (1) WO2020050241A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008735A (es) 2021-01-29 2023-08-01 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para el tratamiento de cancer pediatrico.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (es) 1970-02-17 1975-03-19
JPS4918630B1 (es) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
ATE172463T1 (de) 1994-08-04 1998-11-15 Hoffmann La Roche Pyrrolocarbazol
BR9709301A (pt) 1996-05-01 1999-08-10 Univ Mississipi Inibidores da proteína quinase c halo-substituídos
CZ20012338A3 (cs) 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2000069856A1 (en) 1999-05-14 2000-11-23 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
BRPI0407757A (pt) 2003-02-28 2006-02-14 Inotek Pharmaceuticals Corp derivados de benzamida tetracìclica e métodos de uso dos mesmos
DE60305634T2 (de) 2003-03-07 2006-09-21 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
PL1687305T3 (pl) 2003-11-21 2008-12-31 Novartis Ag Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
US7687524B2 (en) 2003-12-12 2010-03-30 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2005092062A2 (en) 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
BRPI0508969A (pt) 2004-03-19 2007-08-21 Speedel Experimenta Ag compostos orgánicos
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN1976903A (zh) 2004-06-02 2007-06-06 法莫西克立克斯公司 因子VⅡa抑制剂
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
US20080292608A1 (en) 2005-11-07 2008-11-27 Irm Llc Compounds and Compositions as Ppar Modulators
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CL2007003049A1 (es) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
EP2474549A1 (en) 2007-04-17 2012-07-11 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
KR101636312B1 (ko) 2007-07-20 2016-07-05 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 활성인 치환된 인다졸 유도체
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
WO2009113420A1 (ja) 2008-03-13 2009-09-17 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
CN102574830A (zh) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US9126931B2 (en) 2009-06-10 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
WO2012023597A1 (ja) 2010-08-20 2012-02-23 中外製薬株式会社 ４環性化合物を含む組成物
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
KR102412321B1 (ko) 2014-04-25 2022-06-22 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
CA2946268A1 (en) 2014-04-25 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体
CN106928184B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Also Published As

Publication number Publication date
SG11202100983XA (en) 2021-03-30
KR20210053890A (ko) 2021-05-12
IL281079A (en) 2021-04-29
BR112021001145A2 (pt) 2021-04-20
JP7167171B2 (ja) 2022-11-08
AU2019337018B2 (en) 2024-03-07
JPWO2020050241A1 (ja) 2021-08-30
EP3848361A1 (en) 2021-07-14
EP3848361A4 (en) 2022-06-15
CN112585126A (zh) 2021-03-30
CA3107270A1 (en) 2020-03-12
US20220372025A1 (en) 2022-11-24
WO2020050241A1 (ja) 2020-03-12
TWI825163B (zh) 2023-12-11
TW202024050A (zh) 2020-07-01
KR102635225B1 (ko) 2024-02-07
AU2019337018A1 (en) 2021-03-18
US11939322B2 (en) 2024-03-26
CN112585126B (zh) 2024-05-07
AR116113A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
PH12020550246A1 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
SA518400053B1 (ar) عملية مُحسنة لإنتاج حمض أكريليك
PH12019502673A1 (en) Novel aspartokinase variant and method for producing l-amino acid using the same
MX2015016947A (es) Metodos para producir derivados de acido graso omega-hidroxilados.
PH12019500493A1 (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
NZ738925A (en) Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
MY168412A (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
MY172601A (en) Improved process for preparing fermented soybean meal
TR201907789T4 (tr) Kalkobutrol hazirlanişina yöneli̇k yöntem
MX2019005319A (es) Método de preparación e intermediario de derivado de un anillo heteroaromático de seis miembros pirrolo.
SG10201902609TA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
SA519410407B1 (ar) طريقة لتحضير مركب وسيط من مشتق 4 - ميثوكسي بيرول
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2021003070A (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino.
MA40255A (fr) Production d'acide lysergique par modification génétique d'un champignon
MX2020006040A (es) Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.
MX2019013872A (es) Metodo para producir material no tejido de celulosa sintetizada bacterianamente.
MX2021002311A (es) Metodo para producir un compuesto tetraciclico.
EA202191502A1 (ru) Способ получения апиксабана
PH12015502121A1 (en) Novel processes for producing sovaprevir
MY165659A (en) Novel method of preparing benzoimidazole derivatives
WO2018007973A3 (en) Process and intermediates for preparing benzoxazepines
SE1551246A1 (en) Modified wood product and a process for producing said product
NZ800483A (en) Processes for preparing arimoclomol citrate and intermediates thereof
MX2016016075A (es) Metodo y composicion para mejorar la productividad de plantas no leguminosas.